α-Galactosylceramide potently augments M2e-induced protective immunity against highly pathogenic H5N1 avian influenza virus infection in mice

Vaccine

Volumn 29, Issue 44, 2011, Pages 7711-7717

  Li, Kai ^a,b   Luo, Jing ^a,b   Wang, Chengmin ^a   He, Hongxuan ^b  

^a INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Galactosylceramide; Highly pathogenic H5N1 influenza virus; Influenza vaccine; M2e

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ANTISERUM; BINDING PROTEIN; GAMMA INTERFERON; GLYCOLIPID; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 4; PEPTIDE; PROTEIN M2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; AVIAN INFLUENZA; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; IMMUNOGENICITY; INFLUENZA A (H5N1); MORBIDITY; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, VIRAL; FEMALE; GALACTOSYLCERAMIDES; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; INTERLEUKIN-4; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VIRAL LOAD;

EID: 80053611847     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.136     Document Type: Article

References (28)

1. Webby R.J., Webster R.G. Are we ready for pandemic influenza?. Science 2003, 302(November (5650)):1519-1522.
2. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5(October (10)):1157-1163.
3. Feng J., Zhang M., Mozdzanowska K., Zharikova D., Hoff H., Wunner W., et al. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 2006, 3:102.
4. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22(August (23-24)):2993-3003.
5. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26(January (2)):201-214.
6. Song J.M., Wang B.Z., Park K.M., Van Rooijen N., Quan F.S., Kim M.C., et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 2011, 6(1):e14538.
7. Wu F., Huang J.H., Yuan X.Y., Huang W.S., Chen Y.H. Characterization of immunity induced by M2e of influenza virus. Vaccine 2007, 25(December (52)):8868-8873.
8. Wu F., Yuan X.Y., Li J., Chen Y.H. The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine. Vaccine 2009, 27(July (32)):4320-4324.
9. Lamb R.A., Zebedee S.L., Richardson C.D. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985, 40(March (3)):627-633.
10. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172(May (9)):5598-5605.
11. De Filette M., Ramne A., Birkett A., Lycke N., Lowenadler B., Min Jou W., et al. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 2006, 24(January (5)):544-551.
12. Fiers W., De Filette M., Birkett A., Neirynck S., Min Jou W. A " universal" human influenza A vaccine. Virus Res 2004, 103(July (1-2)):173-176.
13. Denis J., Acosta-Ramirez E., Zhao Y., Hamelin M.E., Koukavica I., Baz M., et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008, 26(June (27-28)):3395-3403.
14. El Bakkouri K., Descamps F., De Filette M., Smet A., Festjens E., Birkett A., et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011, 186(January (2)):1022-1031.
15. Godfrey D.I., MacDonald H.R., Kronenberg M., Smyth M.J., Van Kaer L. NKT cells: what's in a name?. Nat Rev Immunol 2004, 4(March (3)):231-237.
16. Brigl M., Brenner M.B. CD1: antigen presentation and T cell function. Annu Rev Immunol 2004, 22:817-890.
17. Lindqvist M., Persson J., Thorn K., Harandi A.M. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J Immunol 2009, 182(May (10)):6435-6443.
18. Huang Y., Chen A., Li X., Chen Z., Zhang W., Song Y., et al. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide. Vaccine 2008, 26(March (15)):1807-1816.
19. Gonzalez-Aseguinolaza G., Van Kaer L., Bergmann C.C., Wilson J.M., Schmieg J., Kronenberg M., et al. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 2002, 195(March (5)):617-624.
20. Schotsaert M., De Filette M., Fiers W., Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009, 8(April (4)):499-508.
21. Galli G., Pittoni P., Tonti E., Malzone C., Uematsu Y., Tortoli M., et al. Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci USA 2007, 104(March (10)):3984-3989.
22. Salomon R., Hoffmann E., Webster R.G. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc Natl Acad Sci USA 2007, 104(July (30)):12479-12481.
23. Ishikawa H., Tanaka K., Kutsukake E., Fukui T., Sasaki H., Hata A., et al. IFN-gamma production downstream of NKT cell activation in mice infected with influenza virus enhances the cytolytic activities of both NK cells and viral antigen-specific CD8+ T cells. Virology 2010, 407(November (2)):325-332.
24. Moran T.M., Isobe H., Fernandez-Sesma A., Schulman J.L. Interleukin-4 causes delayed virus clearance in influenza virus-infected mice. J Virol 1996, 70(August (8)):5230-5235.
25. Baskin C.R., Bielefeldt-Ohmann H., Tumpey T.M., Sabourin P.J., Long J.P., Garcia-Sastre A., et al. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci USA 2009, 106(March (9)):3455-3460.
26. Guillonneau C., Mintern J.D., Hubert F.X., Hurt A.C., Besra G.S., Porcelli S., et al. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci USA 2009, 106(March (9)):3330-3335.
27. Li X., Fujio M., Imamura M., Wu D., Vasan S., Wong C.H., et al. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci USA 2010, 107(July (29)):13010-13015.
28. Kopecky-Bromberg S.A., Fraser K.A., Pica N., Carnero E., Moran T.M., Franck R.W., et al. Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine 2009, 27(June (28)):3766-3774.